TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23235363
Drug: telmisartan 160
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: telmisartan 160 mg as monotherapy
Study: 16078963
Drug: Newer drugs
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newer drugs
Study: 24952730
Drug: Older agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Older agents
Study: 10025924
Drug: Interferon-alpha (IFNalpha)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha (IFNalpha) 13.5 x 10(6) units per week in divided doses
Study: 3902105
Drug: Pimozide 2
Normalized name: pimozide 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimozide 2 mg or 6 mg
Study: 3902105
Drug: Thioridazine 25
Normalized name: thioridazine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thioridazine 25 mg or 75 mg
Study: 3902105
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of pimozide and thioridazine
Study: 30810462
Drug: Hydrogel bulking
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogel bulking agent (Bulkamid®)
Study: 30810462
Drug: Collagen gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen gel (Contigen®)
Study: 26306566
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement containing β-hydroxy-β-methylbutyrate (HMB), glutamine and arginine (3g HMB, 14g glutamine, 14g arginine daily for 6 months)
Study: 21352670
Drug: Traditional standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional standard chest physical therapy
Study: 17725180
Drug: Stavudine 40
Normalized name: stavudine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stavudine 40 mg capsules (Ranbaxy Laboratories Ltd.)
Study: 17725180
Drug: Zerit 40
Normalized name: Zerit 40mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zerit 40 mg capsules (Bristol-Myers Squibb)
Study: 9891830
Drug: Angioplasty with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angioplasty with high Lp (a) levels (above 0.30 g/l)
Study: 7241682
Drug: Cinoxacin 500
Normalized name: cinoxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinoxacin 500 mg twice daily for 10 days
Study: 7241682
Drug: Trimethoprim-sulfamethoxazole 160-800
Normalized name: sulfamethoxazole
DrugBank: Sulfamethoxazole (DB01015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole 160-800 mg twice daily for 10 days
Study: 28646784
Drug: 30min of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30min of morning light therapy (5,000lx; blue-enriched polychromatic light, 17,000K)
Study: 26216608
Drug: Nasal balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal balloon autoinflation 3 times daily for 1-3 months plus usual care
Study: 22935321
Drug: High blueberry
Approvals — FDA: no, EMA: no, PMDA: no
Description: High blueberry dose (75 g)
Study: 22935321
Drug: Low blueberry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low blueberry dose (35 g)
Study: 22935321
Drug: Control (ascorbic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (ascorbic acid and sugar matching high blueberry dose)
Study: 8141279
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (0.03 mg.kg ideal body wt‐1.day‐1)
Study: 2183716
Drug: Endotracheal tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Endotracheal tobramycin (40 mg every 8 h)
Study: 6107407
Drug: Cholecalciferol (vitamin
Normalized name: cholecalciferol (vitamin D3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (vitamin D3) 3000 units (75 micrograms) daily
Study: 6107407
Drug: 1,25-dihydroxycholecalciferol 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,25-dihydroxycholecalciferol 1 microgram daily
Study: 28152124
Drug: Subretinal injection
Normalized name: LUXTURNA Suspension for Subretinal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subretinal injection of 0.1 mL of a gene therapy solution containing 1 × 10^11 viral particles
Study: 23172847
Drug: Lifestyle treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle treatment programme with physiotherapist involvement
Study: 23172847
Drug: Lifestyle treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle treatment programme without physiotherapist involvement
Study: 21216670
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg once per day, orally) for 3 months starting 5-10 days after stroke onset
Study: 17382151
Drug: Lidocaine ointment
Normalized name: Lidocaine Ointment
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine ointment combined with tramadol drops 1 mg/kg per os 40 minutes before the procedure (group 2)
Study: 17382151
Drug: 5% lidocaine
Normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lidocaine ointment 5 mL per rectum 10 minutes before the procedure (group 1)
Study: 15245526
Drug: Wet wrap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wet wrap therapy (WWT) with 1% hydrocortisone (HC) applied once in the morning for 2 weeks, wet wraps twice daily for week 1, and only at night for week 2
Study: 15245526
Drug: Hydrocortisone (HC)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone (HC) applied twice daily without wet wraps
Study: 11753990
Drug: Radiotherapy (RT),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy (RT), mean total dose 65 grays (Gy; 62.3-70 Gy)
Study: 11753990
Drug: Deferred treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred treatment (DT)
Study: 9669469
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (IVMP) pulse therapy (2 g)
Study: 3154322
Drug: Chronic versus
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic versus single digoxin dosing
Study: 26092311
Drug: Dopamine D2-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine D2-receptor antagonist sulpiride (400 mg)
Study: 22752050
Drug: Risedronate 150-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 150-mg once a month
Study: 22752050
Drug: Risedronate 5-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 5-mg daily
Study: 20964572
Drug: 2% sunflower
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% sunflower oleodistillate (SO) cream applied twice a day
Study: 20964572
Drug: Hydrocortisone butyro-propionate
Normalized name: propionate
DrugBank: Propionate ion (DB19384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone butyro-propionate 1 mg/g applied twice a day
Study: 18164562
Drug: 17beta‐estradiol 1mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17beta‐estradiol 1mg plus norethisterone acetate 0.5 mg (E(2)/NETA)
Study: 18164562
Drug: raloxifene HCl
Normalized name: raloxifene HCl
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: raloxifene HCl 60 mg
Study: 16418760
Drug: Gx (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gx (500 mg capsules containing 6 mg synephrine, 150 mg caffeine, and 150 mg catechin polyphenols)
Study: 14593356
Drug: Ticlopidine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (500 mg BID loading dose for 2 days and 250 mg BID for subsequent 5 days)
Study: 14593356
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg loading dose and 75 mg/day for subsequent 6 days)
Study: 11001866
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day prednisolone
Study: 6389477
Drug: Enoxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxacin (400 mg twice daily for 14 days)
Study: 12131781
Drug: Loxiglumide 300
Normalized name: Dexloxiglumide
DrugBank: Dexloxiglumide (DB04856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxiglumide 300 mg/d
Study: 12131781
Drug: Loxiglumide 600
Normalized name: Dexloxiglumide
DrugBank: Dexloxiglumide (DB04856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxiglumide 600 mg/d
Study: 12131781
Drug: Loxiglumide 1200
Normalized name: Dexloxiglumide
DrugBank: Dexloxiglumide (DB04856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxiglumide 1200 mg/d
Study: 10220845
Drug: Supervised physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised physical therapy rehabilitation (1 h, twice weekly) with emphasis on balance training
Study: 10220845
Drug: Supervised physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised physical therapy rehabilitation
Study: 7823670
Drug: Face-washing intervention
Normalized name: Phisoderm Clear Confidence Daily Gel Face Wash
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-washing intervention program plus mass topical antibiotic treatment
Study: 7823670
Drug: Mass topical
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass topical antibiotic treatment only (Control)
Study: 31309627
Drug: Topical product
Normalized name: Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical product containing 3 antioxidants (pre‐tocopheryl®, retinaldehyde, glycylglycine ole‐amide)
Study: 31309627
Drug: Positive antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive antioxidant control cream
Study: 28412590
Drug: Ramucirumab treatment
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ramucirumab treatment for CEA ≤10 subgroup
Study: 28412590
Drug: Ramucirumab treatment
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ramucirumab treatment for CEA >10 subgroup
Study: 28412590
Drug: Ramucirumab treatment
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ramucirumab treatment
Study: 25468160
Drug: Obeticholic acid
Normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Obeticholic acid (25 mg daily for 72 weeks)
Study: 23245591
Drug: Meperidine (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (0.7 mg/kg) with sham patient controlled analgesia (Group M)
Study: 23245591
Drug: Remifentanil 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.5 μg/kg with patient-controlled analgesia pump (Group R1)
Study: 23245591
Drug: Remifentanil 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.8 μg/kg with patient-controlled analgesia pump (Group R2)
Study: 21460373
Drug: Isoniazid (INH)
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid (INH) combined with Antiretroviral therapy (ART)
Study: 17522096
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (exercise and manipulation)
Study: 9543282
Drug: inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled corticosteroids
Study: 9543282
Drug: oral corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral corticosteroids
Study: 8297217
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg IV DMT
Study: 8297217
Drug: 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg IV DMT
Study: 8297217
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg IV DMT
Study: 8297217
Drug: 0.05 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg IV DMT
Study: 4357135
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate 400 mug daily
Study: 26294143
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (antibiotics at physician's discretion)
Study: 17727576
Drug: Behavioural modification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural modification (moderation of fluid intake or timing of taking anti-diuretic medication)
Study: 17727576
Drug: Antimuscarinic agents
Normalized name: ANTIMUSCARINICS/ANTISPASMODICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimuscarinic agents or desmopressin (a nona-peptide analogue of anti-diuretic hormone)
Study: 10867212
Drug: Heparin-induced extracorporeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-induced extracorporeal LDL/fibrinogen precipitation (HELP)
Study: 9100583
Drug: Thyroxine dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroxine dose changes
Study: 7691426
Drug: Aprotinin 1
Normalized name: aprotinin 1.4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin 1 million KIU (200,000 KIU bolus followed by 100,000 KIU/hr infusion for 8 hours)
Study: 20144858
Drug: Long-term humidification
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term humidification therapy
Study: 18564957
Drug: Directly applied
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly applied mud pack treatment (heated mud, up to 43 degrees C, applied directly for 30 minutes, 15 applications)
Study: 18564957
Drug: Nylon-covered mud
Normalized name: NYLON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nylon-covered mud pack treatment (same treatment as study group but with nylon cover)
Study: 9884381
Drug: Epinephrine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine (10 micromol/L)
Study: 9884381
Drug: Zinterol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinterol (10 micromol/L)
Study: 9884381
Drug: Norepinephrine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine (10 micromol/L)
Study: 1884968
Drug: 1:10000 adrenalin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1:10000 adrenalin injection
Study: 1884968
Drug: 1:10000 adrenalin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1:10000 adrenalin +1% aethoxysclerol injection
Study: 22253296
Drug: 1,000 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg/d of elemental calcium carbonate plus 400 IU/d of vitamin D(3)
Study: 20598973
Drug: Intracoronary administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary administration of autologous bone marrow mononucleated cells (BM‐MNCs) at 5 to 7 days after AMI
Study: 20598973
Drug: Intracoronary administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary administration of autologous bone marrow mononucleated cells (BM‐MNCs) at 3 to 4 weeks after AMI
Study: 15613506
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (3 mg/kg/day) in the iron supplemented (IS) group; n = 37
Study: 10536353
Drug: Conventional smear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional smear (CS) preparation
Study: 25526014
Drug: Fit Minded
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fit Minded Tablet (n=15)
Study: 24030535
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hyaluronic acid (HA) and tamarind seed polysaccharide (TS‐polysaccharide)
Study: 19954391
Drug: Methylprednisolone aceponate
Normalized name: Methylprednisolone aceponate
DrugBank: Methylprednisolone aceponate (DB14643)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone aceponate 0.1% cream
Study: 10773104
Drug: Cyclical etidronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclical etidronate therapy (400 mg/day for 14 days every 3 months) followed by 500 mg/day of elemental calcium for 1 year
Study: 10773104
Drug: Placebo followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo followed by 500 mg/day of elemental calcium for 1 year
Study: 8643695
Drug: Cladribine 0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cladribine 0.10 mg/kg per day for 7 days as four monthly courses (total 2.8 mg/kg)
Study: 8643695
Drug: Cladribine i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cladribine i.v. infusions of 0.10 mg, 0.05 mg, and 0.05 mg per kg of body weight per day for 7 consecutive days in three successive monthly courses (total 1.4 mg/kg)
Study: 26087884
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise intervention (cycling for at least 15 minutes daily for 15 months)
Study: 20739450
Drug: Almond skin
Normalized name: Bodi Line Almond Skin Cleanser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almond skin phenolic extract (884 mg of total polyphenols/dose)
Study: 16463656
Drug: L-carnitine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (12 g/L in ST. Thomas cardioplegia)
Study: 11996470
Drug: Schedule A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule A (carboplatin AUC 4 with topotecan 0.5 or 0.75 mg/m2)
Study: 11996470
Drug: Schedule B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule B (carboplatin AUC 4 with topotecan 0.5 or 0.75 mg/m2)
Study: 7655177
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hip axis length and bone mineral density
Study: 7655177
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Singh grade, hip axis length, and bone mineral density
Study: 2119677
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tenoxicam once daily for 8 days (days 5-12)
Study: 2119677
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg glibenclamide once daily for 12 days
Study: 2119677
Drug: Mean oral
Normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean oral clearance of tenoxicam
Study: 26034367
Drug: Modified sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified sequential therapy (Group B): ilaprazole at 5 mg bid, amoxicillin and clavulanate potassium at 914 mg for the first five days, followed by ilaprazole at 5 mg bid, furazolidone at 100 mg bid, and levofloxacin at 500 mg qid for the next five days.
Study: 26034367
Drug: Standard quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard quadruple therapy (Group A): ilaprazole + bismuth potassium citrate + amoxicillin and clavulanate potassium + levofloxacin.
Study: 17420159
Drug: Peppermint oil
Normalized name: Peppermint Oil
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peppermint oil (two enteric-coated capsules twice per day)
Study: 15815889
Drug: Inpatient topical
Normalized name: Impatiens balsamina flowering top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient topical treatment with dithranol and narrow band UV‐B 311 nm
Study: 15815889
Drug: Biologics treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologics treatment with efalizumab
Study: 11964576
Drug: High-volume preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume preparation of botulinum toxin-A (60 units)
Study: 11964576
Drug: Low-volume preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume preparation of botulinum toxin-A (60 units)
Study: 8749612
Drug: Physostigmine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine administered by steady-state, continuous intravenous infusion
Study: 2677915
Drug: Conservative functional
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative functional treatment
Study: 29699717
Drug: Telephone referral
Normalized name: teferrol
DrugBank: Iron polymaltose (DB15763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone referral from Primary Health Care to Internal Medicine Consult
Study: 29699717
Drug: Traditional referral
Normalized name: teferrol
DrugBank: Iron polymaltose (DB15763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional referral from Primary Health Care to Internal Medicine Consult
Study: 19491016
Drug: (99m)Tc-NC100692, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: (99m)Tc-NC100692, intravenous injection of 150 micrograms
Study: 16982293
Drug: Meropenem 500
Normalized name: meropenem 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 500 mg intravenously every 8 hours
Study: 16982293
Drug: Imipenem/cilastatin 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin 500 mg intravenously every 8 hours
Study: 15579755
Drug: Androstenedione (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androstenedione (100 mg)
Study: 8361987
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg regular aspirin daily (14 pills)
Study: 8361987
Drug: 325 mg
Normalized name: lysine 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg regular aspirin daily (14 pills)
Study: 8361987
Drug: 325 mg
Normalized name: lysine 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg enteric-coated aspirin daily (14 pills)
Study: 8361987
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg regular aspirin every other day (7 pills)
Study: 8361987
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg daily aspirin
Study: 3791663
Drug: Pirenzepine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (100 mg p.o. at 2200 and 2400 h)
Study: 29388085
Drug: Intra-articular combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular combined with intraosseous injection of PRP (administered twice, 2 weeks apart)
Study: 29388085
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of PRP (every 14 days)